THE 5-HT6 RECEPTOR ANTAGONIST PLATFORM

The best selective and multi-target serotonin 5-HT6 receptor antagonists to treat the cogmitive disorders of Alzheimer’s disease, Huntington’s disease, Schizophrenia, Down’s syndrome and other CNS diseases associated cognitive disfunctions.

A SELECTIVE 5-HT6 RECEPTOR ANTAGONIST PLATFORM

The best in class AVN-211 in Schizophrenia is in Phase II/III Clinical trial.
AVN-322 is ready in Phase II Clinical trials in Alzheimer disease.
Backup compounds AVN-3085, AVN- 3205 are in preclinical development.
AVN-211, AVN-322, AVN-3085, and AVN- 3205 possess excellent DMPK/tox and behavioral profiles.

A MULTI-TARGET PLATFORM

Drug candidat AVN-101 is now in clinical development for Alzheimer’s disease and anxiety. Both molecules possess excellent DMPK/tox and behavioral profiles. Backup compound AVN-0189 is in preclinical development.
Both molecules possess excellent DMPK/tox and behavioral profiles.

pipline

AVN 211 AVN 322 AVN 101 AVN 3085 AVN 3205 AVN 0189